BioTissue Holdings, Inc. Strengthens Commitment to Eye Care
BioTissue Holdings, Inc. has made significant strides in solidifying its focus on ocular innovation. The company has recently finalized the sale of its non-ocular Surgical and Wound Care business to BioStem Technologies, marking a pivotal change in its operational strategy.
Details of the Strategic Sale
The transaction grants BioStem exclusive rights to the Neox and Clarix product lines, both valued assets in the market. BioTissue's Surgical sales team, along with core support staff, will be integrated into BioStem's operations. This partnership ensures that BioTissue will continue to manufacture these products while redirecting its resources towards enhancing interventional therapies aimed at treating ocular surface conditions.
Future Focus on Ocular Therapies
With a sharpened focus, BioTissue aims to innovate and provide comprehensive solutions for conditions that deeply affect patients' quality of life. The product line under development includes Prokera, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard. These offerings will facilitate advanced treatment protocols while ensuring educators and healthcare providers receive the necessary support and training.
Company Insights from Leadership
“Our vision has always centered around transforming patient care through cutting-edge regenerative therapies,” stated Ted Davis, President and CEO of BioTissue. He emphasized that this divestiture allows the organization to hone in on advancements in eye care, ultimately leading to improved patient outcomes. Davis expressed gratitude towards the Surgical team for their dedication, noting that their integration with BioStem will foster continued innovation.
BioStem's Growth Vision
Jason Matuszewski, BioStem's CEO, acknowledged the foundation established by BioTissue in surgical and wound care sectors. He highlighted how BioTissue's strengths will complement BioStem's existing offerings, creating fresh opportunities for growth and improved patient outcomes through enhanced commercial execution.
About BioTissue Holdings, Inc.
BioTissue is at the forefront of medical innovation, focused on harnessing the unique properties of human birth tissue for regenerative healing. The company specializes in addressing acute and chronic ocular surface conditions, employing its proprietary CryoTek cryopreservation technology to preserve the biological integrity of its cryopreserved amniotic membrane products.
Pioneering Regenerative Medicine
The organization actively contributes to the field of regenerative medicine through several Investigational New Drug applications and seeks Biologic License Applications for groundbreaking therapies. With a robust portfolio that has been utilized in over one million procedures, BioTissue exemplifies its commitment to improving patient care quality through scientific innovation.
Their advancements in ocular treatments are backed by over 420 peer-reviewed publications, underscoring the clinical relevance and effectiveness of their technologies. The company encourages healthcare professionals to utilize their solutions to enhance patient recovery experiences.
Conclusion: A New Chapter for BioTissue
This strategic shift positions BioTissue to lead in ocular innovation while ensuring that the valuable technologies developed for surgical and wound care continue to benefit practitioners and patients alike under BioStem's stewardship. The commitment to ocular care today sets the stage for a future where patient outcomes are greatly improved through targeted therapeutic innovations.
Frequently Asked Questions
What prompted BioTissue to sell its Surgical and Wound Care business?
BioTissue aimed to concentrate its efforts on eye care innovation, viewing the divestiture as a strategic opportunity for enhanced focus and growth in ocular therapies.
What are the primary products BioTissue will focus on after the sale?
Post-sale, BioTissue plans to develop products like Prokera, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard for acute and chronic ocular conditions.
Who will take over BioTissue's Surgical and Wound Care sales team?
The Surgical sales team and support staff will become part of BioStem Technologies, integrating into their commercial operations to continue serving their client base.
How does BioTissue ensure quality in its products?
BioTissue employs proprietary CryoTek technology to maintain the integrity of its amniotic membrane products, alongside a commitment to evidence-based practices.
What role does research play in BioTissue's mission?
Research is central to BioTissue’s mission, as evidenced by their significant number of peer-reviewed publications and ongoing investigational applications aimed at addressing unmet clinical needs in ocular health.
